StemCell Therapy

Global Personalized Medicine market size will reach xx million US$ by 2025, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2019-2025 as the forecast period to estimate the market size for Personalized Medicine .

This industry study presents the global Personalized Medicine market size, historical breakdown data (2014-2019) and forecast (2019-2025). The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Personalized Medicine market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-1511

Global Personalized Medicine market report coverage:

The Personalized Medicine market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Personalized Medicine market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The following manufacturers are covered in this Personalized Medicine market report:

Key Players

Some key players in this market are Roche Holding AG, Astra Zeneca PLC, Vertex Pharmaceuticals Inc., Qiagen Inc., BD (Becton Dickinson & Co., Merck & Co. Inc., Pfizer Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc. among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

APEJ (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-1511

The study objectives are Personalized Medicine Market Report:

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-1511

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Personalized Medicine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Continue reading here:
Personalized Medicine Market is Anticipated to Attain a Market Value of US$XX by the End of 2016 2026 - Cole of Duty

The use of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making may seem more aspirational than practical at times, but that state of affairs is changing rapidly. Wendy Rubenstein, director of personalized medicine at the U.S. FDAs Center for Devices and Radiological Health, said contemporary versions of these real-world sources of evidence are of progressively higher quality in recent years, and thus RWE and RWD may soon hit their strides as mature sources of data with which regulators are increasingly comfortable.

Rubenstein was speaking on a recent webinar hosted by the Medical Device Innovation Consortium, the public-private partnership between the FDA and device makers with the objective of modernizing regulatory science. The theme of the webinar was a framework developed by MDIC for the use of RWE and RWD for in vitro diagnostics, and Rubenstein said that for perhaps the majority of randomized, controlled trials, the benefit is generally diluted when that therapy or diagnostic is rolled out for routine clinical use. The external validity of the results of studies is not always sufficiently vigorous to withstand translation into general clinical use, particularly when the enrolled study population fails to reflect the population(s) that will use or receive the device, she said.

Collection of RWD in the premarket phase should help mitigate these problems and more accurately predict similar results in real-world settings, Rubenstein said, adding that RWDs reputation has not always been the best and has maybe got a bit of a bad rap as a consequence. Recently, however, the increasing quality of RWE and RWD is changing minds, and Rubenstein said the process involved in developing the MDIC framework is helping us get to that higher level.

Pandemic has quickened stakeholder interest

The FDA has given the nod to more than 100 diagnostic emergency use authorizations (EUAs) in connection with the COVID-19 pandemic, and Rubenstein said the pandemic has had the effect of unifying the purpose of regulators and test developers alike. COVID-19 can actually result in driving the community toward a common purpose of generating evidence on real test performance for molecular diagnostics for the SARS-CoV-2 virus, she said, but this will require a definition of common data elements to support use purposes. Still, Rubenstein advised that the pandemic is likely to come to an end before stakeholders can stand up a fully developed infrastructure needed to make routine use of RWD.

In other words, theres an opportunity to use the activation energy created by the pandemic to build an infrastructure that will extend beyond COVID, Rubenstein said. However, all of this will require the use of the Standardization of Lab Data to Enhance Patient-Centered Outcomes and Value-Based Care (Shield) project. Shield is another public-private partnership, and is focused on data lab standards, and is one of the pillars needed to make the data accessible. The development of mapping manuals for logical observation identifier names and codes (LOINCs) will also prove crucial because of a considerable amount of ambiguity with regard to LOINCs, which has up to now has made it difficult to aggregate data about a tests routine clinical use, sometimes even within a health care organization.

Danelle Miller, director of global regulatory policy at Indianapolis-based Roche Diagnostics Corp., and chair of the RWE working group (WG) at MDIC, made reference to the August 2017 FDA guidance for the use of RWE to support regulatory decision-making. Miller said industry welcomed the FDA guidance enthusiastically, largely because the guidance goes a long way toward clarifying when RWE can be leveraged for regulatory decision-making. She said the MDIC framework represents years of hard work and robust discussions among the parties, including industry, the FDA and the Centers for Disease Control and Prevention. The comment period for the MDIC framework closes June 15.

The scope of the framework is largely limited to the current landscape for RWE and real-world data (RWD) and, in the case of the latter, how it can be used for both premarket regulatory decision-making and for postmarket issues. The framework also proposes and approach for evaluating the relevance and reliability of RWD to assess data quality for regulatory decisions, and proposes a few study designs and methods for generating valid scientific evidence.

The task for the work groups included development of a glossary for RWE and RWD, as well as a survey to determine how IVD manufacturers are currently using RWE throughout product life cycles. The WG undertook a literature search for use of RWE and RWD, but there was a considerable amount of effort put into a description of the requirements for data quality and the methods for using RWD.

Alternative study designs available

One of the complicating factors in leveraging real-world sources of evidence for diagnostics in the premarket phase is that diagnostic studies dont often strongly resemble the types of trials employed for therapeutic devices. One approach to overcoming this limitation is the use of a virtual clinical performance study, which can be used to support premarket approval or clearance of an IVD. The MDIC paper spells out several other approaches as well, but among the regulatory considerations for any of these studies is whether the data are fit for the purpose at hand.

The assessment to determine whether those data are fit for purpose includes a determination of whether the data are both accurate and complete, and whether those data meet key reliability and relevance criteria to support the sought-after regulatory decision. Test developers should also ensure they are using data standards the FDA will accept, and may want to engage with the agency via the Q-submission process to clear out any potential issues before the developer invests more than a modest amount of resources toward the application.

Visit link:
Real-world data coming into its own despite bad reputation in times gone by - BioWorld Online

Drug Discovery Informatics MarketScope

The GlobalDrug Discovery Informatics Marketstood at USD 1,680.6 million in 2017. It is expected to enjoy a high valuation at a 11.5% CAGR from 2018 to 2023 (forecast period). Factors driving market growth include impending need to curtail drug discovery and development costs, focus on drug discovery, increasing expenditure on R&D, and large prevalence of chronic diseases. According to the WHO report of 2001, chronic diseases accounted for 60% of the deaths that year. Nearly 46.4% of the deaths in 2020 will be credited to chronic diseases triggering the market demand. But setup of laboratories and high costs of informatics software can restrict the market growth.

Drug discovery plays a vital role in the life sciences, pharmaceutical, and biopharmaceutical industries. The amount of data accumulated from clinical trials and tests is vast and requires software to sift through. New approaches in drug discovery informatics for accumulating and processing information can lead to faster commoditization of drugs, medicines, and vaccines. The global drug discovery informatics market report by Market Research Future (MRFR) contains a comprehensive overview followed by pertinent factors and drawbacks for the period between 2018 and 2023.

Request Free Sample Copy at:https://www.marketresearchfuture.com/sample_request/7831

Drug Discovery Informatics MarketSegmentation

The global drug discovery informatics market is segmented by product, mode, service, and end-user.

By product, drug discovery informatics market is segmented into discovery informatics and development informatics.

By mode, drug discovery informatics market is is divided into in-house informatics and outsourced informatics.

By service, drug discovery informatics market is is segmented into clinical trial data management, sequencing and target data analysis, molecular modeling, docking, and others. The sequencing and target data analysis segment is touted to dominate the market during the forecast period due to increasing applications in targeted analysis. Inclination towards personalized medicine is bound to drive the segment demand and contribute to the global drug discovery informatics market growth.

By end-user, drug discovery informatics market is is segmented into contract research organizations, pharmaceutical & biotechnology industries, and others.

Drug Discovery Informatics Market Regional Analysis

Europe, Asia Pacific (APAC), the Americas, and the Middle East & Africa (MEA) are regions covered in the global drug discovery informatics market report.

The Americas dominated the global market in 2017 due to presence of prominent names such as International Business Machines, PerkinElmer Inc., and ThermoFisher Scientific Inc. Establishment of next-generation sequencing and chemical laboratories in the U.S. and Canada, boom in pharmaceutical and biopharmaceutical industries, and sophisticated healthcare infrastructure.

Europe is the second largest region and highly lucrative for the global drug discovery informatics market till 2023. This can be credited to funding allocated to research and development on drug research by governments, growth in therapeutic discovery centers, and successful activities by research and academic institutes, universities, and other prestigious centers.

APAC can be ensured to display a profitable growth rate during the forecast period due to the large geriatric population and heavy prevalence of chronic diseases. Awareness of the software, adoption of the software in pharma and biopharma companies, and a rise in clinical studies can drive the regional market growth. Lower costs, lax policies and regulations, and a spurt in clinical trials are other factors making the region lucrative for the global drug discovery informatics market.

Drug Discovery Informatics Market Competitive Outlook

Certara, L.P., Charles River Laboratories, Inc., Jubilant Life Sciences Ltd., Novo Informatics Pvt. Ltd., Dassault Systmes, IO Informatics, Inc., Thermo Fisher Scientific, Inc., Infosys Limited, Selvita, International Business Machines Corporation, PerkinElmer, Inc., Collaborative Drug Discovery Inc., and GVK Biosciences Private Limited are prominent players of the global drug discovery informatics market.

Drug Discovery Informatics Industry News

Schrdinger, a U.S. based drug discovery company, recently received nearly USD 232 million in funding in January 2020. The platform developed by the company can assess the chemical composition of molecules and predict the properties during mixing and expedite the process rapidly saving production costs in the process.

Browse More Details at:https://www.marketresearchfuture.com/reports/drug-discovery-informatics-market-7831

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [emailprotected]

Read the rest here:
Drug Discovery Informatics Market Size Estimation, Future Insights, Growth Dynamics, COVID-19 Impact and Applications By 2023 - Cole of Duty

The battle against COVID-19 is dominating our attention right now and rightly so. The pandemic is impacting economies, societies and individuals across all sectors, but especially in healthcare. However, while we focus on tackling the pandemic, it is critical that we dont lose sight of our efforts to address the devastating impact of other diseases, such as cancer.

With healthcare systems focused on the fight against COVID-19, we are witnessing disruption across the spectrum of cancer care and delivery. There are multiple contributing factors, ranging from closures of screening programmes to public transport lockdowns hindering access to health facilities, delays to important consultations leading to disease progression and high rates of sickness among health workers dramatically reducing the numbers of available staff. Cancer patients are also more vulnerable to becoming severely ill or dying from COVID-19 and many, understandably, fear coming into hospitals or clinics during this time.

Nowhere is the battle against cancer fought more bitterly than in Asia Pacific (APAC). Almost half of the worlds cancer cases are found here, and by 2030 the number of people battling cancer is expected to surge by around 35%, with mortality rising by almost 40%. COVID-19 has emphasised the importance of making health systems robust and sustainable in the long-term, so that the impact of care delivery for non-communicable diseases like cancer is minimized during this and future outbreaks.

When addressing significant public health issues like COVID-19, cardiovascular disease or cancer can sometimes feel like an insurmountable challenge for countries faced with limited resources and competing priorities.

A new report from the Economist Intelligence Unit (EIU), supported by Roche, analyses the readiness of 10 APAC countries to address the cancer challenge. The report highlights existing gaps and progress made with recommendations on how to boost this progress towards more sustainable and equitable cancer care. Advances in cancer planning and preparedness vary across countries, but the improvements highlighted span several areas from research and policy development to the expansion of national cancer registries and implementation of universal health coverage (UHC) programmes.

Australia ranks highest of all countries evaluated for overall cancer preparedness, followed by Malaysia, South Korea, China and Thailand. This success is due in part to these countries demonstrating strong examples of cancer registries, which play a vital role in generating meaningful, evidence-based, long-term planning for cancer. The Philippines stands out as one of the only lower-middle-income countries evaluated with a comprehensive cancer plan.

Cancer preparedness in APAC

Image: Economist Intelligence Unit, Roche

We also see a strong link between a countrys cancer readiness and its overall healthcare spending. Indonesia and Malaysia showed strong commitment in this area; they registered the strongest growth in healthcare spending of all the countries evaluated, with average annual increases of 5.7% and 3.2% respectively. The WHO notes higher government spending on health is also associated with lowering income inequality, in particular for fast-growing countries.

Spending more on health is a way to reduce inequality

Image: WHO Health Expenditure Report 2019

UHC generates benefits to societies far beyond the health sector, strengthens health systems governance and improves overall population health outcomes. Across Asia, positive steps have been taken towards universal access to cancer care. Thailand demonstrates strong implementation of UHC programmes alongside higher-income countries like Australia, South Korea and Japan. Thailand is also the only country evaluated in which all cancer medicines were found to be fully accessible and reimbursable via their public health system, an impressive achievement unmatched even in highly developed nations. This increased focus on UHC programmes is in line with the recent WHO report that recommends the inclusion of prevention, early diagnosis, screening and appropriate treatment of non-communicable diseases in essential personalised healthcare services and UHC benefit packages.

Theres no getting away from the fact that the COVID-19 crisis has magnified healthcare challenges for populations and, in turn, policy and decision-makers. So how do we double down on this progress in a post-COVID-19 world to ensure we continue along a faster, upwards trajectory?

Gaps in service availability experienced by middle-income countries like China, Malaysia, Indonesia and the Philippines, including the under-provision of equipment, oncology specialists and infrastructure, are a major area of opportunity. If COVID-19 has shown us anything, it is that digital technology can play a critical role in addressing these gaps. The pandemic has forced healthcare systems to adopt new ways of working, to ensure cancer patients continue to receive essential care. Places like Thailand and Hong Kong are reaching more patients in need through the launch of virtual clinics and teleconsultations for remote areas. Australia and China are harnessing artificial intelligence to aid faster, more accurate diagnosis.

There is also a clear need to establish strong, cross-sector partnerships to collaborate on research and invest in areas like big data analytics and personalised medicine to significantly improve patient outcomes.

In Taiwan, for instance, Roche is partnering with the government to foster personalized healthcare with a focus on tailoring cancer treatment to individual patients for the best outcomes. The objective is to provide targeted treatment through precise genomic analysis and to reduce unnecessary medical expenses while improving the quality of healthcare.

Each year, $3.2 trillion is spent on global healthcare making little or no impact on good health outcomes.

To address this issue, the World Economic Forum created the Global Coalition for Value in Healthcare to accelerate value-based health systems transformation.

This council partners with governments, leading companies, academia, and experts from around the world to co-design and pilot innovative new approaches to person-centered healthcare.

While progress is undoubtedly being made in tackling the cancer challenge across APAC, there is still a long way to go. Excess cancer mortality remains a serious concern for lower-and middle-income countries. Cancer not only takes lives but also can result in severe economic hardship.

As someone who has spent a significant amount of time in healthcare and seen first-hand the devastating impact of the pandemic on cancer patients, I believe that a data-driven future holds the most potential to build resilient health systems for the future. Better data can help us work smarter and faster to respond to issues like COVID-19 and future health challenges. Digital and personalised healthcare can play an important role in advancing UHC, making health systems more sustainable, efficient and accessible and allowing policy-makers to better optimise resources.

Reducing the cancer burden requires an integrated, cross-sector, global response. This means creating systemic change in our healthcare ecosystems, and reorienting our relationships with the government, the outside world, and even with each other. While testing the limits of our health systems, COVID-19 has also highlighted the incredible achievements possible when we all band together.

See more here:
What's working in the APAC countries' fight against cancer? - World Economic Forum

Anti-CD20 monoclonal antibodies are widely used in the treatment of B-cell malignancies. Anti-CD20 monoclonal antibodies are advantageous as they have enhanced killing activities and improves CD20 levels on the cell surface to increase the activity of lymphoma therapy. Since the inception of monoclonal antibodies, various type of potential mechanisms has been developed to increase the therapeutic efficiency of anti-CD20 monoclonal antibodies. This laid emphasis on developing next generation of anti-CD20 monoclonal antibodies to supplement additional potency in terms of functionality and efficacy. Anti-CD20 monoclonal antibodies work by targeting expressed CD20 marker on mature B cells and malignant B cells. This cascade of series works by complementing with the marker to deliver immunological attack from complement and FcR-expressing innate effectors (macrophages). This result in producing transmembrane signals by CD20 on engagement with anti-CD20 monoclonal antibodies, this favorable mechanism is utilized in malignant disease and autoimmune disorder treatment. Potential benefits from anti-CD20 monoclonal antibodies laid emphasis on developing next-generation anti-CD20 monoclonal antibodies and are currently in clinical trials.

To remain ahead of your competitors, request for a sample [emailprotected]https://www.persistencemarketresearch.com/samples/20833

The market for anti-CD20 monoclonal antibodies is primarily driven by increasing research and development activities in generating potent anti-CD20 monoclonal antibodies. Various research funding and grants, and investment are done by both private and government bodies to support R&D activities and are driving the growth of anti-CD20 monoclonal antibodies market. In addition, rising demand for personalized medicine coupled with increasing use of immunotherapy, and potential benefits from the treatment in terms of fewer side effects, low cost of production are also impelling the market growth of anti-CD20 monoclonal antibodies. However, the high cost of production, the presence of alternative therapies such as chemotherapy and drugs, and stringent rules and regulations are the major obstacles to the growth of anti-CD20 monoclonal antibodies market.

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/20833

The global anti-CD20 monoclonal antibodies market can be segmented on the basis of product type, end-user, and region.

The introduction of monoclonal antibodies has revolutionized targeted therapy for cancer. Since its introduction, various technological advancement has been made in generating a novel products such as next generation anti-CD20 monoclonal antibodies are humanized monoclonal antibodies, whereas first generation anti-CD20 monoclonal antibodies are chimeric monoclonal antibodies. In addition, some of the anti-CD20 monoclonal antibodies are enhanced to improve effector functions, including improvement in FcR binding sites. The emergence of logistic services and e-commerce websites are also a vital component in boosting the growth of anti-CD20 monoclonal antibodies market.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/methodology/20833

Geographically, global anti-CD20 monoclonal antibodies market can be segmented into North America, Latin America, Europe, Asia-Pacific and Middle East & Africa. The market in North America is anticipated to show the largest market share for anti-CD20 monoclonal antibodies, followed by Europe, owing to the presence of sophisticated healthcare infrastructure. In addition, proper reimbursement of therapy procedure, and increasing awareness about personalized medicine among the general population are also gardening the market growth of anti-CD20 monoclonal antibodies. The market in Asia-Pacific region is estimated to grow at fastest CAGR over the forecast period owing to the presence of large population base, and increasing research and development activities supported by private and public bodies. However, the market in the Middle East & Africa shows the steady growth during the forecast period.

Some of the market participants in the global anti-CD20 monoclonal antibodies market are

Read the original here:
Demand for Anti Cd2-0 Monoclonal Antibodies Market to Witness Rapid Surge During the Period 2017 2025 - Cole of Duty

July 22nd, 2020

12:00 PM - 1:00 PM ET

Whether you have been named power of attorney or have named someone to act as yours, it is crucial to understand the legal obligations and restrictions of power of attorney and living wills.

In this webinar, Whitney OReilly will provide tips and tricks for getting the most out of your power of attorney or living will, from making sure the appropriate parties are informed of their role to establishing a way of communicating the directives to hospitals, living facilities, and financial managers. She will highlight some of the key questions individuals should ask in the process of determining their power of attorney and creating living wills and will review the impact recent legislation has had on the power of attorney and living wills.

This webinar will feature a brief Q&A with Michael Snyder, who recently worked with the firm to manage the legal ramifications of sickness and death. Michael is the chair of the Department of Genetics and the director of the Center for Genomics and Personalized Medicine at Stanford University School of Medicine.

Read more:
[Webinar] The Dos and Donts of Power of Attorneys and Living Wills - July 22nd, 12:00 pm - 1:00 pm ET - JD Supra

MantHealth (NH) offers cancer molecular profiling solutions that enable personalization in a number of cancer treatments. This business, which has been lingering for a couple of years has received an important FDA approval which makes approval for Medicare and Medicaid use very likely. This, together with the sale of their Connected Care business has boosted the stock price significantly, but we think it's not too late to step on board.

The company is also is enabling a more integrated and data-driven healthcare solution through its two SaaS platforms, which are growing and account for most of the company's revenues to date.

These proven integration solutions are offered to an industry, which as they claim (and, dare we say, not without reason) suffers from a host of unnecessary complexity and inefficiencies, most notably:

Because of these inhibitions, the healthcare system is struggling to make the shift towards a more holistic, data-driven approach, the culmination of which is individualized medicine.

Personalized medicine is based on personalized data that is increasingly becoming available through advances in molecular medicine and real-time biometrics (remote monitoring devices and the like).

These solutions, like the company's own GPS business, generate a veritable deluge of data which, for a coordinated and individualized approach need to be collected, analyzed and distributed, and it's here where the company's SaaS solutions intervene and add value. We'll quickly introduce the company's solutions below.

From the 10-K:

GPS Cancer is a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing, providing oncologists with insights into the unique molecular signature of a patients cancer to inform personalized treatment strategies.

What GPS Cancer does is comparing the patient's whole genome/exome sequencing of a persons tumor sample with their normal sample in order to highlight molecular alterations that are specific to their tumor DNA.

These alterations are then subsequently confirmed by RNA sequencing. All this enables the matching of these alterations with drugs that might be effective against tumors containing the specific change. And these solutions are constantly fine-tuned by machine learning.

This is the company's blood based test that allows non-invasive profiling of tumors and monitoring quantitative response to treatment, from the 10-K:

Liquid GPS looks beyond cfDNA to cfRNA, which allows profiling and trending of actionable biomarkers that cannot be assessed through cfDNA alone. In addition to providing molecular insight into key guidelines-based biomarkers (e.g., EGFR, ALK, ROS1, KRAS), this powerful RNA-based approach enables a variety of capabilities and applications not typically available from a liquid biopsy test.

It is able to monitor targeted therapies, immunotherapy and chemotherapy responses.

This is the company's SaaS based decision support system which provides evidence-based clinical decision support for physicians who are threatened to be overwhelmed by today's rapid advancements in molecular and biometric medicine.

Eviti centralizes stuff like clinical content, treatment cost from Medicare reimbursements and treatment toxicity data. It has access to over 7600 clinical trials and 4000+ evidence-based treatment regimes.

NaviNet Open is a payer-provider workflow collaboration platform in order to increase efficiency, lower cost, improve provider satisfaction and enable communication between health plans and providers.

The company sold its Connected Care business for $47M in February to Masimo (MASI), exiting DCX, VCX, HBox and Shuttle Cable. The Connected Care business generated $1.2M in sales in Q1, a small part of overall revenue ($23M).

While operational performance has improved, the company hasn't been able to grow much in the past four years:

Data by YCharts

After the sale of its Connected Care business, the company has two revenue categories:

To date, the company's SaaS revenue generates most of its revenue but it does gain some revenue from sequencing and molecular analysis. However, last quarter saw a big decline to just $59K (down from $814K a year ago).

The stagnant revenue in part is just appearance as the company's SaaS business has been growing, from $60.7M in 2017 to $65.6M in 2018 to $72.8M in 2019, because the company de-emphasized its GPS business as costs were outweighing revenues. The company keeps on adding new customers (like here and here) to its SaaS businesses, a few were mentioned on the Q1CC.

The company keeps improving their products and adding new Eviti and NaviNet features.

For this business to take off, the wait is basically for a positive coverage determination from CMS, from the Q1CC:

we expect to continue to see minimal sequencing and molecular analysis revenue impact until we receive a positive coverage determination from CMS.

However, that event seems near, from the 10-K (our emphasis):

In the fourth quarter of 2019, we received FDA 510(K) authorization for Omics Core, the nations first FDA authorized whole exome tumor-normal in vitro diagnostic (IVD) that measures overall tumor mutational burden (TMB) in cancer tissue, completing a key step towards achieving Medicare coverage.

Which, together with the sale of the Connected Care business, explains the rally in the shares, from FinViz:

It's GPS business generated $2.55M in revenues in 2017, $3.13M in 2018 and $1.73M in 2019. Here too, apart from the FDA approval for Omics Core, there are other developments and improvements.

The company launched a new AI platform which can automatically distinguish sub-types lung cancer pathology and improves on that ability, from PR:

Derived from deep-learning models, together, the findings demonstrate a novel AI-based method for subtyping lung cancer pathologies which impacts treatment options for patients and improved methods of identifying tumor infiltrating white cells found elevated in lung cancer.

Accurately identifying and quantifying tumor-infiltrating white cells is extremely important for prognosis and treatment decisions in this era of personalized medicine, yet it currently requires manual review of whole slide images by medically trained pathologists, and incurs significant delays and cost, explains Dr. Patrick Soon-Shiong, MD, Chairman and CEO of NantHealth.

And they are working on a similar solution for breast cancer. In principle, their TMB (tumor mutational burden) test capability is a generic capability with wide application scope, here is a description of the mechanics from company PR:

Omics Core reports a cancer patient's overall TMB by sequencing and comparing 19,396 protein-coding genes targeting 39 million base pairs of the human genome from a tumor sample and a normal sample, typically from blood or mucosal membrane. TMB indicates the sum of all acquired gene-coding mutations in a tumor genome and is increasingly used to predict response to therapy and identify tumors that could benefit from immunotherapy. In addition, the test reports somatic mutations in 468 cancer-relevant genes accurate to 2% allele frequency, to inform clinical decisions about patient treatment. "Tumor mutation burden ... is now recognized as a key biomarker across multiple tumor types," said Patrick Soon-Shiong, chairman and CEO of Nanthealth. "Studies have shown that immunotherapy treated with high TMB had better outcomes compared to those with low TMB."

And here is a description of a peer reviewed article how this improves targeting capabilities of treatments. It's the more general applicability of TMB and the FDA approval that shareholders are rejoicing.

According to management, two things stand out (PR, our emphasis):

Nanthealth is positioning its tumor-normal test as an advancement over competitors like Myriad Genetics Inc., Color Genomics Inc. and Invitae Corp., which have limited gene panels to look at hereditary risk. By sequencing the whole exome, "we have the ability to identify things that others are missing, and that's particularly critical for drug development," Sandeep Reddy, Nanthealth's chief medical officer, told BioWorld MedTech. "We know about maybe cancer risk, but what do we know about autism or Alzheimer's? By getting that information, that becomes transformative."

As described in that PR, the company's TMB test spots things that other solutions don't, resulting in a more personalized approach to what therapies might be more successful, and it has applicability beyond screening for cancers.

But from a financial point of view, things are also going pretty well.

Data by YCharts

GAAP margins have been trending up and gross margin was much better than a year ago (60% versus 49%), up on product mix (the shift towards its SaaS business).

Operating expenses declined from $20.2M in Q1 2019 to $16.8M in Q1 2020, but $1.1M of that decline is related to the sold Connected Care business.

While cash flow is still negative, there has been tremendous improvement in the last 2.5 years.

Data by YCharts

The net cash burn in Q1 was still around $5M, but this included various closing costs and other front-end loaded costs in relation to the sale of the Connected Care business.

And with that sale the balance sheet has improved a lot, with the company having $47.5M in cash on the books, although the company does have a substantial $95.3M in long-term debt, from the 10-Q:

Data by YCharts

The valuation has jumped along with the share price recently but we think it's still not excessive, it has been much higher in the past on a much more distant promise of monetizing their TMB solutions and in the meantime the company developed a successful SaaS business with their Eviti and NaviNet platforms.

With a backwards looking EV/S of 8X for a company with a unique product that is about to get monetized and a successful SaaS business is high, but not overly so. Analyst still expect EPS losses, $0.23 this year falling to -$0.18 next year, but the company doesn't burn much cash and has plenty of it.

While much is uncertain about the potential of the company's GPS business and the economics of it, the company does have unique capabilities that are likely to become important tools in fighting a number of cancers and the underlying capabilities seem to have wide applicability.

Add to that an attractive SaaS business a declining cash burn and the sale of its Connected Care business providing enough cash to keep the company going for the foreseeable future, and we think we still have an attractive proposition for shareholders, even if it looks like the shares might want to have to digest recent strong gains.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Excerpt from:
NantHealth Points To The Future Of Healthcare - Seeking Alpha

WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (IM Therapeutics), a leading innovator in the field of precision medicine for autoimmune disease, announced today that Mr. Tom Shea and Dr. Sarah Bird have joined its senior management team. Tom has joined as Chief Financial Officer and Chief Operating Officer (CFO/COO) and Sarah has been promoted to the position of Vice President, Clinical Development.

Tom has over 30 years of professional financial experience ranging from early-stage start-ups to commercial-stage and publicly traded companies. Most recently, Tom served as CFO of ImmusanT, a clinical stage therapeutic company in celiac disease and type 1 diabetes. He has served as CFO and has been involved in growth operations of a number of biotech companies, most notably Albireo Pharma, developing products for children with severe liver diseases, Tolerx, Inc., an immunology company focused on type 1 diabetes, and Cubist Pharmaceuticals, an infectious disease company. Over his career, Tom has led executive teams in raising significant capital and completing transactions for strategic collaborations. In addition, Tom has served as a Board Member of the New England chapter of JDRF, a world-renowned foundation devoted to the treatment and cure of T1D.

Sarah joined IM Therapeutics at its founding stage to help design and lead its clinical program development as Director, Clinical Development. She is a seasoned professional with over 20 years experience leading programs in basic, translational and clinical research. She has worked in academia, biotech and device industries in technologies from start-up to commercial stage. In her graduate and postdoctoral work at St Louis School of Medicine and later as a JDRF Fellow at the U. of Colorado, her research focused on autoimmune pathogenesis and potential therapeutic approaches. Sarah has led global programs at Medtronic, Gilead and pharmaceutical companies in both clinical and medical affairs managing cross-functional teams responsible for strategy, planning and execution. Sarah has led teams overseeing regulatory submissions and product approvals while actively raising physician and patient awareness in areas of unmet medical need.

I am excited to be working closely with Sarah and Tom as we advance our clinical programs and grow our pipeline, said Nandan Padukone, Ph.D., CEO of IM Therapeutics. Both Tom and Sarah have shown a great commitment to T1D and to bringing new drug programs in autoimmune disease to the clinic.

I find the underlying biology that genetically targets specific autoimmune pathogeneses to be fascinating and a unique opportunity to translate to clinical practice, said Dr. Bird. It is great to work with highly motivated people to impact patient care and personalized medicine, she added.

Mr. Shea further added, Ive had a long-standing interest in helping to progress companies working within the autoimmune space. I am pleased to be a part of this team and very hopeful of the targeted approach we are testing in T1D and other autoimmune diseases.

The Company recently announced that the first subject was dosed in a Phase 1 study of its lead drug, IMT-002, an oral drug designed as a selective HLA-DQ8 blocker for treatment of T1D and DQ8-related disease.

About IM Therapeutics

IM Therapeutics is a clinical stage company developing personalized medicines for autoimmune diseases by building oral drug therapies against human leukocyte antigen (HLA) variants that confer high risk of disease. The Company platform screens millions of compounds for optimal docking within HLA proteins together with rational drug design and bioassays to develop targeted therapeutic candidates. In addition to its lead drug, IMT-002, directed at HLA-DQ8 activity for treatment of type 1 diabetes, the Company is building a broad pipeline of drugs against HLA targets such as DQ2, DR3 and DR4 in a range of autoimmune disorders including celiac disease. http://imtherapeutics.com/

Go here to read the rest:
IM Therapeutics Expands Management Team with Appointments of Tom Shea as CFO/COO and Dr. Sarah Bird as VP, Clinical Development - Business Wire

KING OF PRUSSIA, Pa., July 9, 2020 /PRNewswire/ --Global biotherapeutics leader CSL Behring today announced the recipients of its 2020 Professor Heimburger Awardfor coagulation research just ahead of the first ever virtual congress of the International Society on Thrombosis and Hemostasis (ISTH).

The annual global Professor Heimburger Awards program recognizes the clinical and/or preclinical research of emerging coagulation specialists who are driven to improve the care of patients with bleeding disorders.The program demonstrates the company's continuing promise to support pioneering research by providing a 20,000 (~$22,500) research grant annually, to each of five recipients. This year's recipients are:

"Our leadership in hemophilia and other bleeding disorders starts with innovative science and extends beyond what is happening in our own labs or product portfolio to advance research and patient care across the globe," said Antti Kourula, Vice President, Hematology Therapeutic Area, CSL Behring."We look forward to the exciting research the Heimburger Awards supports."

In addition, CSL Behring will highlight its continued commitment to scientific research and innovation by participating as a Gold level sponsor at ISTH 2020 Virtual Congress. During the Congress, CSL Behring will host two symposia and two product theaters, along with supporting eight posters. (Full abstracts may be reviewed at https://abstracts.isth.org/)

CSL Behring Supported Symposia & Product Theaters (Tuesday, July 14, 2020)

CSL Behring Supported Posters

About the CSL Behring Professor Heimburger AwardsProfessor Norbert Heimburger was an employee of CSL Behring for more than 30 years and devoted his work to blood coagulation. One of his major contributions in this area was the development of virus-safe plasma products based on pasteurization, a development that led CSL Behring to produce the world's first virus-inactivated factor VIII concentrate to treat patients with hemophilia. More information about the Professor Heimburger Awards, including application information for 2021 can be found at: https://www.cslbehring.com/r-and-d/awards-and-grants/professor-heimburger-award

About CSL BehringCSL Behringis a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, anddelivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.

SOURCE CSL Behring

Link:
CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress - PRNewswire

Gravity can be a real downer when you are trying to grow organs.

Thats why experiments in space are so valuable. They have revealed a new perspective into biological sciences, including insights into making human tissues.

Gravity influences cellular behavior by impacting how protein and genes interact inside the cells, creating tissue that is polarized, a fundamental step for natural organ development. Unfortunately, gravity is against us when we try to reproduce complex three dimensional tissues in the lab for medical transplantation. This is difficult because of the intrinsic limitations of bio-reactors used on Earth.

I am a stem cell biologist and interested on brain health and evolution. My lab studies how the human brain is formed inside the womb and how alterations in this process might have lifelong consequences to human behavior, such as in autism or schizophrenia. Part of that work includes growing brain cells in space.

To build organized tissues in the lab, scientists use scaffolds to provide a surface for cells to attach based on a predetermined rigid shape. For example, an artificial kidney needs a structure, or scaffold, of a certain shape for kidney cells to grow on. Indeed, this strategy helps the tissue to organize in the early stages but creates problems in the long run, such as eventual immune reactions to these synthetic scaffolds or inaccurate structures.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

By contrast, in weightless conditions, cells can freely self-organize into their correct three-dimensional structure without the need for a scaffold substrate. By removing gravity from the equation, we researchers might learn new ways of building human tissues, such as cartilage and blood vessels that are scaffold-free, mimicking their natural cellular arrangement in an artificial setting. While this is not exactly what happens in the womb (after all the womb is also subject to gravity), weightless conditions does give us an advantage.

And this is precisely what is happening at the International Space Station.

These experiments help researchers optimize tissue growth for use in basic science, personalized medicine and organ transplantation.

But there are other reasons why we should manufacture organs in space. Long-term space missions create a series of physiological alterations in the body of astronauts. While some of these alterations are reversible with time, others are not, compromising future human spaceflights.

Studying astronauts bodies before and after their mission can reveal what goes wrong on their organs, but provides little insights on the mechanisms responsible for the observed alterations. Thus, growing human tissues in space can complement this type of investigation and reveal ways to counteract it.

Finally, all forms of life that we know about have evolved in the presence of microgravity. Without gravity, our brains might have evolved in a different trajectory, or our livers might not filter liquids as it does on Earth.

By recreating embryonic organ formation in space, we can anticipate how the human body in the womb would develop. There are several research initiatives going on in my lab with human brain organoids at ISS, designed to learn the impact of zero gravity on the developing human brain. These projects will have profound implications for future human colonization (can humans successfully reproduce in space?). These studies will also improve the generation of artificial organs that are used for testing drugs and treatments on Earth. Will better treatments for neurodevelopmental and neurodegenerative conditions that affects millions of people come from research in space?

More:
Why are scientists trying to manufacture organs in space? - The Conversation US

The healthcare sector has started to utilize the patient engagement technology so that they can offer them with better treatments.

FREMONT, CA:Technology is continuously changing the face of the healthcare industry at an extremely high rate. If the new technologies are utilized effectively, healthcare organizations will meet the increasing demand and efficiently offer better service to the patients. Here are some of the trends related to patient engagement technology that the healthcare sector can follow.

Utilization of artificial intelligence (AI) and machine learning

Presently, the healthcare sector has also started to utilize technologies like machine learning and AI. However, it is expected that the utilization of these technologies will increase rapidly in the coming years and offer various benefits. Moreover, if the sector enhances their research and clinical trials' efficiency by developing new tools, it will help them to fulfill the demands of the patients and even make the process cost-efficient.

The opinion about technologies like chatbots is also changing because the patients can directly book their appointments or solve their queries related to medications. Moreover, Conversational AI will also help the patients and the healthcare providers to converse among each other through written or spoken language.

Advancement of personalized treatment using predictive medicine

Presently various new applications are coming up that are prioritizing predictive healthcare so that the patients get introduced to more effective treatments. Wearables are a useful technology that can be used for capturing the data for treatment purposes. Therefore, the healthcare sector is applying wearable technologies to create opportunities for organizations to offer personalized treatment to the patients.

Furthermore, the data that has been collected from the smartwatches and trackers will allow the healthcare facilities to get a better idea and start treatment of the issues in advance before it starts showing symptoms in the patients. The doctors can also prescribe the medications accurately due to precision medicine as it is data driven.

The continuous growth of digital platforms

As the consumers want a better and sophisticated service so that they can manage their necessities, the popularity of the all-in-one platform is increasing. In the healthcare sector, the consumers are also expecting a user-friendly and customer-first digital experience, and this all-in-one platform can offer them with it.

However, in the healthcare sector, it is necessary to apply the new technologies in their present business model and IT infrastructure to offer better treatment to their patients.

See also:Top Machine Learning Companies

See original here:
How Patient Engagement Technology is Transforming the Healthcare... - Healthcare Tech Outlook

Genomics Market report highlights CAGR value fluctuations during the forecast period of 2020-2025 for the market. The report presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market. A market research analysis and estimations carried out in this Genomics report aids businesses in gaining knowledge about what is already there in the market, what market looks forward to, the competitive background and steps to be followed for outdoing the rivals. Furthermore, market research report also provides a watchful investigation of the current state of the market which covers several market dynamics.

Businesses can accomplish unparalleled and comprehensive insights along with the best acquaintance of the emerging market opportunities with this Genomics market research report. This report is structured with the meticulous efforts of innovative, enthusiastic, knowledgeable and experienced team of analysts, researchers, industry experts, and forecasters. By understanding clients requirements precisely, this report brings together business and product information for the sustainable growth in the market. Two of the major tools of market analysis employed are SWOT analysis and Porters Five Forces Analysis. The Genomics report is generated with a nice combination of advanced industry insights, practical solutions, talent solutions and the use of latest technology which gives an excellent user experience.

Get the inside scope of the Sample report @https://www.theinsightpartners.com/sample/TIPTE100000730/

MARKET INTRODUCTION

The global genomics market is expected to reach US$ 32,995.3 Mn in 2025 from US$ 14,728.6 in 2017. The market is estimated to grow with a CAGR of 10.8% from 2018-2025.

Genomics market is segmented by technology, product & services, application and end user. Global genomics market, based on technology was segmented into sequencing, microarray, PCR, nucleic acid extraction and purification, and others. Global genomics market, based on the product & services was segmented into instruments/systems, consumables, and services. The genomics market, based on application was segmented into diagnostics, drug discovery & development, precision/personalized medicine, agriculture & animal research and others. The genomics market is bifurcated on basis of end user such research centers, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users.

Key Competitors In Market are

The top 10 industry players operating in the market of genomics across the globe includes Thermo Fisher Scientific Inc., Illumina Inc., and Eurofins, Qiagen, Agilent Technologies, BGI, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Danaher, and GE Healthcare. For instance, in October 2017, MGI Tech, a subsidiary corporation of BGI, launched two new next generation genetic sequencers, MGISEQ-2000 and MGISEQ-200 in Shenzhen, China. MGI also launched a modular NGS workstation, MGIFLP along with other products. And the launch expanded the business of the company in global genomics market.

TOC of Market Report Contains:

MARKET SCOPE

The objective of the study is to describe, define, and forecast the genomics market by technology, product & services, application, end user and region. The report also provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and trends). The report helps to analyze market with respect to individual growth trends, prospects, and contributions to the overall market.

Market segmentation:

Genomics Market to 2025 Global Analysis and Forecasts by Technology (Sequencing, Microarray, PCR, Nucleic Acid Extraction and Purification, and Others), Product & Service (Instruments/Systems, Consumables, and Services), Application (Diagnostics, Drug Discovery and Development, Precision/Personalized Medicine, Agriculture & Animal Research, and Others) End User (Research Centers, Hospitals and Clinics, Pharmaceutical & Biotechnology Companies, and Others) and Geography

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

Click to buy full report with all description:https://www.theinsightpartners.com/buy/TIPTE100000730/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Read more:
Genomics Market 2020 Insight On The Analysis By Essential Factors And Trends In Industry By 2025 - 3rd Watch News

Post by Lisa Carroll, Canadian Public Sector Lead, Microsoft Canada

As the COVID-19 pandemic unfolded earlier this year, healthcareprovidersacross the country found themselves like so many other organizations having to urgently reinvent ways to operate, provide patient care, manage supply chains and deploy resources, with many of the usual ways of doing things suddenly off the table.With every second counting,the industryquicklyrealizedthat the immediate implementation andredeploymentof valuable resources wasanimperative.

It hasnt been easy, butamidst the crisisand uncertainty, we have continued to persevere.I amtrulyamazed at the incredibletransformationour healthcaresystemhasimplemented in such a short period of time.Healthcare providersquickly pivoted to newways of operating, while also coming together as a community todevelopnew solutionsforsafe and securetesting toprotect the health and wellbeing of our Citizens andsupporting the initiation ofthereopening our economy.

Microsoft has been working closely withpartnersand customersthroughout the pandemicto solve these big challenges by connecting health data and systems in the cloud, making health work better for patients and providers, and advancing precision medicine.Akey priority for us is providingthese organizationswith the peaceof mind to remainconfidentthattheir data is beingprocessed bytrustedMicrosoft platformsthat aresecure and compliant by designmeetingmore than70industry-widecertifications.Recognizing that thehealthcare sector is particularly vulnerable tocyber-attacksduring times of crisis, Microsofthas also recentlyimplementedanintensified monitoring and takedown ofpotentialthreatswith anemphasis on protecting critical services,such ashospitals.

I wanted to take a moment to pause and recognize the resilience and ingenuity of a smallsamplingof the many organizations who areresponding and protectingour communities across Canada:

POWERING THE HEART OF VIRTUAL CARE

POWERING INSIGHTS FOR BETTER PATIENT OUTCOMES

ACCELERATING HEALTHCARE DELIVERY

There is something to be said about hownecessityand emergencyoften drive innovation, andwe are especially proud to becollaboratingwith Citizen Care Pod Corporation,WZMH Architects, PCL Construction and Insight Enterpriseson a new initiative todeveloped with the intent torevolutionizetheaccessibilityand safety of COVID-19 testing.The Citizen Care Pod is a customizable unit outfitted with the capabilities to enable turnkey mobile COVID-19 testing in high-traffic business environments and communities with the goal to expedite testing, screening, and eventually vaccination on mass scale.

Utilizing modular construction methods, PCL Construction is manufacturing and assembling the pods by retrofitting shipping containers with customizable options to support rapid delivery and installation toany site, including high-traffic or remote locations.Eachpodis equipped with a suite of intelligent, customizable technologies powered by Microsofts trusted Azure and AI platform,which support a safe and secure testing environment for patients and front-linehealthcareworkers.

CANADIANS ARESTRONGER TOGETHER

Each passing day of this pandemic bringsnew challenges,butitsbeenincredible to see howgovernments and healthcare organizations across the countryarequickly reinventingways to operateasmany of the changes put in place today will help medical professionals deliver personalized care to Canadians in new, innovative ways in the post-COVID world.

We are proud to be part of new solutionsand new partnerships as we join together in our common cause.As the saying goes, it takes a village and at Microsoft we are committed to being there for all of our customers and partners to weather this storm together.

To learn more about Microsoft solutions that can help in the fight against COVID-19, visitaka.ms/healthcareincanada

More here:
Supporting Canada's Healthcare Industry with Trusted Technology in Response to COVID-19 - Microsoft

Ripple Science Logo

ANN ARBOR, Mich. (PRWEB) July 09, 2020

Ripple Science today announced their partnership with Lakeside Life Science, a diagnostic research organization that is performing a clinical study to determine antibodies using Medsentials COVID-19 IgG/IGM Rapid Test Cassette. With 11.6 Million cases and over 500,000 deaths worldwide, the public health crisis that is COVID-19 has accelerated organizations to adopt technology like Ripple, which shorten time-to-market for biopharma solutions.

Ripple is a web-based platform designed for clinical research teams who want a secure and streamlined way to recruit, manage, and retain patients for trials. Ripple is a purpose-built CRM and project manager which organizes clinical trial recruiting and research efforts, leading to valuable time and cost savings. Medsentials test is already available for high-complexity CLIA certified labs. Lakesides study will be validating the test in a clinical setting. Paul Allard, COO of Lakeside Life Science, explained how Ripple helps with a very short timeline: Ripple is streamlining the whole clinical study process for us. Our timeline for this study is incredibly short. Normally we need four to six months for study start up and 18 months to enroll patients. Our goal is to complete this entire study under a month and a half.

Allard anticipates a follow-on study to determine how long a person has the antibodies. Lakeside, an expert in testing validation, has confirmed that Medsentials IgM/IgG antibody test outperform antibody tests from well-known industry healthcare providers. Allard said, In moving to a long-term study, we want high confidence in our antibody testing solution and are delighted at Medsentials results and how easy the tests are to use.

Lakeside is using Ripple to quickly recruit and track patients from small, underserved community centers that dont have access to standard testing or the tools to manage clinical studies. Patients from these small centers can benefit from access to testing and are more representative of the general population.

Clinical studies are known for their complex nature beginning with recruiting patients to continual patient engagement, especially for follow-up months after the study commences. Chiao-ih Hui, COO for Medsential, is pleased that many of the study complexities are being removed. I love that Ripple is making this highly involved and complex clinical process easier and streamlined. This will accelerate and provide a model for getting our solution to point-of-care settings and to vulnerable populations who have the most need for these solutions.

President and CEO of Ripple Science, Peter Falzon commented, With COVID-19, the way we conduct clinical trials has changed and there is a heightened sense of urgency. The team at Ripple Science is dedicated to enabling clinical research teams to work remotely and adopt virtual research methods, while boosting recruitment and retention.

About Lakeside Life Science:Lakeside Life Science was founded in January of 2015, by W. Jeffrey and Paul Allard to bring patients and communities together to advance personalized medicine through the research and development of novel diagnostic tests. Lakeside provides the resources for their clients to bring their assays from invention to FDA clearance/approval, while putting patient needs first.

About Medsential: Medsential LLC is a US FDA registered company that develops, manufactures, and distributes a broad range of medical products to customers. Established in 2005, Medsential is an ISO certified medical device company with the capabilities to manufacture and assemble a broad range of products. Medsential has an extensive distribution channel, salesforce, engineering platform, and production team to bring quality products to global markets.

About Ripple Science: Ripple Science accelerates clinical research with its secure, HIPAA-compliant suite of tools. By adapting sales and marketing automation to the process of patient recruitment, Ripple helps our customers recruit more participants, faster and reduces patients lost to follow-up. Ripple Sciences flagship product, Ripple, is currently being used by research investigators at more than 100 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia (UK), Cognito Therapeutics (Boston, MA) and the University of Michigan.

To learn more, please visit: https://www.ripplescience.com

Share article on social media or email:

Read more:
Ripple Science Partners with Lakeside Life Science to Accelerate the Clinical Validation Process for Medsential's Point-of-Care COVID-19 Antibody Test...

Dublin, July 03, 2020 (GLOBE NEWSWIRE) -- The "Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company" report has been added to ResearchAndMarkets.com's offering.

The global digital genome market was valued at US$ 11,065.31 million in 2019 and is projected to reach US$ 20,812.81 million by 2027; it is expected to grow at a CAGR of 8.4% during 2020-2027.

The growth of the digital genome market is mainly attributed to factors such as the increasing prevalence of chronic diseases and growing funding for genomics. However, dearth of skilled professionals is likely to restraint the growth of the market during the forecast years.

Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, accounting for US$ 4 billion in at least 14 countries. These national genomic medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implement and gather evidence for broader adoption.

The UK has announced the world's largest genome project as part of 200 million public-private collaboration between charities and pharmaceutical. The UK has already developed the largest genome database in the world through the 100,000 Genomes Project. Led by Innovate UK as part of UK Research and Innovation, the project will fund researchers and industry to combine data and real-world evidence from UK health services and create new products and services that diagnose diseases efficiently.

Moreover, in August 2018, Boston, a Massachusetts-based company, announced that it landed US$ 4.3 million in seed funding and that it would be partnering with Veritas Genetics, a genome sequencing company. The funds will support the company's mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.

Cardiovascular diseases (CVDs) such as atherosclerosis, angina pectoris, and acute myocardial infarction are a significant cause for mortality in the world owing to the present day hectic lifestyle. As per the data provided by WHO, CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can lead to various complications in different parts of the body and can increase the overall risk of premature death.

Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As there is a significant increase in diabetes cases across the world, it results in life-changing complications among the population. According to the International Diabetes Federation (IDF), in 2017, 46 million diabetic patients were reported in North America, which is expected to reach 62 million in 2045. As chronic diseases are increasing at a faster pace, the research on genomics for life-threatening illnesses has progressed rapidly over the last five years, thereby driving the market growth during the forecast period.

Based on product, the digital genome market is segmented into DNA/RNA analysis, sequencing chips, sequencing and analyzer instruments, sample prep instruments, and sequencing and analysis software. The sequencing and analyzer instruments segment held the largest share of the market in 2019; whereas, the sequencing chips segment is estimated to register the highest CAGR in the market during the forecast period.

Based on application, the digital genome market is segmented into diagnostics, agricultural, academic research, drug discovery, personalized medicine, and other applications. The diagnostics segment held the largest share of the market in 2019; however, personalized medicine segment is estimated to register the highest CAGR in the market during the forecast period.

Based on end-user, the global digital genome market is segmented into diagnostics and forensic labs, academic research institutes, hospitals, and others. The diagnostics and forensic labs segment held the highest share of the market in 2019; whereas, the academic research institutes segment is estimated to register the highest CAGR in the market during the forecast period.

Key Topics Covered

1. Introduction1.1 Scope of the Study1.2 Report Guidance1.3 Market Segmentation1.3.1 Global Digital Genome Market - By Product1.3.2 Global Digital Genome Market - By Application1.3.3 Global Digital Genome Market - By End-user1.3.4 Global Digital Genome Market - By Geography

2. Digital Genome Market - Key Takeaways

3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research

4. Global Digital Genome Market - Market Landscape4.1 PEST Analysis4.1.1 North America - PEST Analysis4.1.2 Europe - PEST Analysis4.1.3 Asia-Pacific - PEST Analysis4.1.4 Middle East and Africa - PEST Analysis4.1.5 South and Central America - PEST Analysis4.2 Expert Opinion

5. Digital Genome Market - Key Market Dynamics5.1 Market Drivers5.1.1 Growing Funding for Genomics5.1.2 Increasing Prevalence of Chronic Diseases5.2 Market Restraints5.2.1 Dearth of Skilled Professionals5.3 Market Opportunities5.3.1 Increasing Technological Advancement in Digital Genome Field5.4 Future Trends5.4.1 Increasing Demand for Personalized Medicines5.5 Impact analysis

6. Digital Genome Market - Global Analysis6.1 Global Digital Genome Market Revenue Forecast and Analysis6.2 Global Digital Genome Market, By Geography - Forecast and Analysis6.3 Market Positioning of Key Players

7. Digital Genome Market Analysis - By Product7.1 Overview7.2 Digital Genome Market Revenue Share, by Product (2019 and 2027)7.3 DNA/RNA Analysis7.4 Sequencing and Analyzer Instruments7.5 Sequencing and Analysis Software7.6 Sequencing Chips7.7 Sample Prep Instruments

8. Digital Genome Market - By Application8.1 Overview8.2 Digital Genome Market, by Application, 2019 and 2027 (%)8.3 Diagnostics8.4 Drug Discovery8.5 Academic Research8.6 Personalized Medicine8.7 Agricultural8.8 Others

9. Digital Genome Market - By End-user9.1 Overview9.2 Digital Genome Market, by End-user, 2019 and 2027 (%)9.3 Diagnostics & Forensic Labs9.5 Academic Research Institutes9.6 Hospitals9.7 Other End-users

10. Digital Genome Market - Geographic Analysis10.1 North America: Digital Genome Market10.2 Europe: Digital Genome Market10.3 Asia-Pacific: Digital Genome Market10.4 Middle East & Africa: Digital Genome Market10.5 South and Central America: Digital Genome Market

11. Impact of COVID-19 Pandemic on Global Digital Genome Market11.1 North America: Impact Assessment of COVID-19 Pandemic11.2 Europe: Impact Assessment of COVID-19 Pandemic11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Digital Genome Market - Industry Landscape12.1 Overview12.2 Growth Strategies Done by the Companies in the Market, (%)12.3 Organic Developments12.4 Inorganic Developments

13. Company Profiles13.1 Thermo Fisher Scientific Inc.13.2 F. Hoffmann-La Roche Ltd.13.3 Illumina, Inc.13.4 QIAGEN13.5 GenomeMe13.6 NanoString Technologies, Inc.13.7 BD13.8 bioMerieux SA13.9 GenMark Diagnostics, Inc.13.10 Perkin Elmer, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/bi9red

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post:
Global Digital Genome Market and COVID-19 Impact Assessment 2019-2027 - A $20+ Billion Industry Opportunity with Lucrative Growth Projected for...

The global market for companion diagnostics reached nearly $4.4 billion in 2016. This market is expected to grow from nearly $5.5 billion in 2017 to $25.1 billion in 2022 at a compound annual growth rate (CAGR) of 35.5% for forecasted period 2017 to 2022.

Report Scope:

The scope of the report encompasses the major types of diagnostics technologies that have been used, the various industry structures such as the lab developed tests (LDTs) sector, and the major applications being commercialized and developed by a wide range of company types. It analyzes current market status, examines future market drivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11778

Report Includes:

An overview of the market for companion diagnostics, including existing products on the market and detailed analysis of the competitive environments. Analyses of market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021. Examination of the current state of the industry, new technologies in assay development, and potential novel commercial venues in this area of the healthcare industry. Identification of major commercial sectors in companion diagnostics: oncology related products vs. cardiovascular diseases and other segments. Profiles of major players as well as a list of current companies that have new companion diagnostics products in development.

REASONS FOR DOING THE STUDY

Companion diagnostics represent part of the personalized medicine sector. The companion diagnostics segment has expanded significantly over the past decade from5% to 15% of the overall personalized medicine sector, and is expected to reach close to 25% in the next five years.

CDx are being used both to predict outcome (efficacy and safety) and to monitor the response. The predictive or selective characteristics of CDxs have demonstrated clearvalue to the pharmaceutical industry. For example, CDx assays are being used to select patients for clinical trials, resulting in a smaller number of subjects needed togenerate positive data, which has a clear positive impact on the resources spent in clinical development.

Cancer is increasingly recognized as a heterogenous disease that requires tailored treatment. Patients are being selected for specific chemotherapies and newer targetedtherapeutics with greater confidence that their specific cancers will respond.

SCOPE OF REPORT

The scope of the report encompasses the major types of diagnostics technologies that have been used, the various industry structures such as the lab developed tests (LDTs) sector, and the major applications being commercialized and developed by a wide range of company types. It analyzes current market status, examines future marketdrivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed.

More Info of Impact [emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/11778

See the rest here:
Companion Diagnostics Market Applications, Types and Growing Trends in Industry, Gross Margin and Forecast size COVID-19 2022 - 3rd Watch News

Technavio has been monitoring the tumor (cancer) profiling market and it is poised to grow by USD 4.85 billion during 2020-2024, progressing at a CAGR of 10% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200629005559/en/

Technavio has announced its latest market research report titled Global Tumor (Cancer) Profiling Market 2020-2024 (Graphic: Business Wire)

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Co., bioMrieux SA, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., QIAGEN NV, Siemens Healthineers AG, and Thermo Fisher Scientific Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Increasing cancer research and funding has been instrumental in driving the growth of the market.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Tumor (Cancer) Profiling Market 2020-2024: Segmentation

Tumor (Cancer) Profiling Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40128

Tumor (Cancer) Profiling Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The tumor (cancer) profiling market report covers the following areas:

This study identifies the increasing adoption of personalized medicine as one of the prime reasons driving the tumor (cancer) profiling market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Story continues

Technavio's SUBSCRIPTION platform

Tumor (Cancer) Profiling Market 2020-2024: Key Highlights

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY TECHNOLOGY

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005559/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: http://www.technavio.com/

Read more:
Analysis of COVID-19 Impact: Tumor (Cancer) Profiling Market 2020-2024 | Increasing Cancer Research and Funding to Augment Growth | Technavio - Yahoo...

A special thank you to Kathleen Dickson and Dr. John Bergeron for pointing out that yes, indeed, there are also many women who have made and continue to make significant contributions to health. We have added their additions below, but this list is by no means complete.

From open heart surgery to child-resistant containers, prestigious awards and bombs (not that kind), Canada has a long history of Canadians whose ideas and inventions have played huge roles in defining this nations healthcare.

DNA and cancer

Nada Jabado at McGill affiliated Childrens Hospital is a pioneer in pediatric cancer and her discovery of the role of what is known as the epigenome that marks the DNA in our genes in cancer. She is a leader in innovation in Health research and recognized for her leadership in the application of discoveries to address brain tumours in children.

Insulin

Perhaps the most famous health innovation to come out of Canada, if such a thing can be measured. The arrival of insulin has saved countless lives since its creation in 1922 when Frederick Banting and Charles Best isolated and extracted insulin from the pancreas of dogs. Their Nobel Prize arrived swiftly thereafter in 1923.

Read the original post:
28 cool health things that started with a Canadian - Regina Leader-Post

Personalized medicine is tailoring of a treatment to a specific patient i.e. designing medicine treatment on the basis of diagnosis, disease condition, patient history, body physics, and other factors related to patients and diseases. Personalized medicine is also known as precision medicine, stratified medicine, or P4 medicine.

Read Report Overview https://www.transparencymarketresearch.com/personalized-medicines-market.html

In personalized medicine, diagnostic analysis is often conducted for selecting suitable and best treatments based on the patients genetic content or other molecular or cellular analysis. Personalized medicine has best response and highest safety margin to ensure enhanced patient care by allowing every patient to attain earlier diagnosis, risk assessment, and best treatment. Additionally, personalized medicine offers opportunities to improve health care by lowering overall treatment costs.

Rise in the prevalence of various types of cancer, affordability of personalized medicine therapy in cancer drugs and various other disease indications, less side-effects of personalized medicine therapy, high adoption in developed markets, and development of innovative drugs are factors driving the global personalized medicine market. However, high competition among existing market players, stringent government regulations regarding product approval, and lack of awareness among the rural population in developing economies are likely to hamper the market in the next few years.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=394

The global personalized medicine market is can be segmented based on product, application, distribution channel, and region. In terms of product, the market has been categorized into personalized medicine therapeutics, personalized medicine diagnostics, personalized nutrition & wellness, and personalized medical care. The personalized medicine therapeutics segment has been sub-categorized into pharmaceuticals, genomic medicine, and medical devices. The personalized medicine therapeutics segment is anticipated to hold the largest share of the global personalized medicine market during the forecast period, owing to rise in the prevalence of various types of cancer and chronic diseases.

Based on application, the global personalized medicine market has been divided into cancer management, infectious diseases, central nervous system (CNS) disorders, blood transfusion safety, coagulation therapy, diabetes, autoimmune diseases, cardiovascular diseases, neurology, and psychiatry. The cancer management segment is likely to hold the major share of the global market during the forecast period. Based on distribution channel, the market can be categorized into hospitals pharmacies, retail pharmacies, dietary care centers, and others. Rising prevalence of chronic diseases is likely to boost the market in the near future.

Request for Analysis of COVID19 Impact on Personalized Medicine Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=394

Geographically, the global personalized medicine market can be segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. In terms of revenue, North America dominates the personalized medicine market, followed by Europe. The market in Asia Pacific and Latin America is developing. This trend is expected to continue during the forecast period as well.

Availability of large patient pool, expansion of the health care industry, and rise in government investments in improvement of health care are anticipated to propel the market in these regions. The personalized medicine market in countries such as Brazil, China, and India is projected to expand at a substantial growth rate during the forecast period, due to rise in awareness among people about usage of the personalized medicine therapy to treat various types of cancer and rapid innovations in personalized medicine for various other disorders.

Pre Book Personalized Medicine Market https://www.transparencymarketresearch.com/checkout.php?rep_id=394&ltype=S

Major players operating in the global personalized medicine market are Abbott Laboratories, Merck & Co., Inc., AstraZeneca, Pfizer, Inc., GlaxoSmithKline plc., Novartis AG, Amgen, Inc., Bayer AG, Mylan N.V., Eli Lilly and Company, Bristol Myers Squibb Co., Daiichi Sankyo Company, Ltd., Biogen, Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Novo Nordisk A/S, and Sanofi Genzyme.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Follow this link:
Personalized Medicine Market: Rise in the Prevalence of Various Types of Cancer to Drive the Global Market - Science Examiner

DUBLIN--(BUSINESS WIRE)--Jun 29, 2020--

The "Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company" report has been added to ResearchAndMarkets.com's offering.

The global digital genome market was valued at US$ 11,065.31 million in 2019 and is projected to reach US$ 20,812.81 million by 2027; it is expected to grow at a CAGR of 8.4% during 2020-2027.

The growth of the digital genome market is mainly attributed to factors such as the increasing prevalence of chronic diseases and growing funding for genomics. However, dearth of skilled professionals is likely to restraint the growth of the market during the forecast years.

Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, accounting for US$ 4 billion in at least 14 countries. These national genomic medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implement and gather evidence for broader adoption.

The UK has announced the world's largest genome project as part of 200 million public-private collaboration between charities and pharmaceutical. The UK has already developed the largest genome database in the world through the 100,000 Genomes Project. Led by Innovate UK as part of UK Research and Innovation, the project will fund researchers and industry to combine data and real-world evidence from UK health services and create new products and services that diagnose diseases efficiently.

Moreover in August 2018, Nebula Genomics, a Massachusetts-based company announced that it landed US$ 4.3 million in seed funding and that it would be partnering with Veritas Genetics, a genome sequencing company. The funds will support the company's mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.

Cardiovascular diseases (CVDs) such as atherosclerosis, angina pectoris, and acute myocardial infarction are a significant cause for mortality in the world owing to the present day hectic lifestyle. As per the data provided by WHO, CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can lead to various complications in different parts of the body and can increase the overall risk of premature death.

Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As there is a significant increase in diabetes cases across the world, it results in life-changing complications among the population. According to the International Diabetes Federation (IDF), in 2017, 46 million diabetic patients were reported in North America, which is expected to reach 62 million in 2045. As chronic diseases are increasing at a faster pace, the research on genomics for life-threatening illnesses has progressed rapidly over the last five years, thereby driving the market growth during the forecast period.

Based on product, the digital genome market is segmented into DNA/RNA analysis, sequencing chips, sequencing and analyzer instruments, sample prep instruments, and sequencing and analysis software. The sequencing and analyzer instruments segment held the largest share of the market in 2019; whereas, the sequencing chips segment is estimated to register the highest CAGR in the market during the forecast period.

Based on application, the digital genome market is segmented into diagnostics, agricultural, academic research, drug discovery, personalized medicine, and other applications. The diagnostics segment held the largest share of the market in 2019; however, personalized medicine segment is estimated to register the highest CAGR in the market during the forecast period.

Based on end user, the global digital genome market is segmented into diagnostics and forensic labs, academic research institutes, hospitals, and others. The diagnostics and forensic labs segment held the highest share of the market in 2019; whereas, the academic research institutes segment is estimated to register the highest CAGR in the market during the forecast period.

Key Topics Covered

1. Introduction

1.1 Scope of the Study

1.2 Report Guidance

1.3 Market Segmentation

1.3.1 Global Digital Genome Market - By Product

1.3.2 Global Digital Genome Market - By Application

1.3.3 Global Digital Genome Market - By End-user

1.3.4 Global Digital Genome Market - By Geography

2. Digital Genome Market - Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Global Digital Genome Market - Market Landscape

4.1 PEST Analysis

4.1.1 North America - PEST Analysis

4.1.2 Europe - PEST Analysis

4.1.3 Asia-Pacific - PEST Analysis

4.1.4 Middle East and Africa - PEST Analysis

4.1.5 South and Central America - PEST Analysis

4.2 Expert Opinion

5. Digital Genome Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Funding for Genomics

5.1.2 Increasing Prevalence of Chronic Diseases

5.2 Market Restraints

5.2.1 Dearth of Skilled Professionals

5.3 Market Opportunities

5.3.1 Increasing Technological Advancement in Digital Genome Field

5.4 Future Trends

5.4.1 Increasing Demand for Personalized Medicines

5.5 Impact analysis

6. Digital Genome Market - Global Analysis

6.1 Global Digital Genome Market Revenue Forecast and Analysis

6.2 Global Digital Genome Market, By Geography - Forecast and Analysis

6.3 Market Positioning of Key Players

7. Digital Genome Market Analysis - By Product

7.1 Overview

7.2 Digital Genome Market Revenue Share, by Product (2019 and 2027)

7.3 DNA/RNA Analysis

7.4 Sequencing and Analyzer Instruments

7.5 Sequencing and Analysis Software

7.6 Sequencing Chips

7.7 Sample Prep Instruments

8. Digital Genome Market - By Application

8.1 Overview

8.2 Digital Genome Market, by Application, 2019 and 2027 (%)

8.3 Diagnostics

8.4 Drug Discovery

8.5 Academic Research

8.6 Personalized Medicine

8.7 Agricultural

8.8 Others

9. Digital Genome Market - By End-user

9.1 Overview

9.2 Digital Genome Market, by End-user, 2019 and 2027 (%)

9.3 Diagnostics & Forensic Labs

9.5 Academic Research Institutes

9.6 Hospitals

9.7 Other End-users

10. Digital Genome Market - Geographic Analysis

10.1 North America: Digital Genome Market

10.2 Europe: Digital Genome Market

10.3 Asia-Pacific: Digital Genome Market

10.4 Middle East & Africa: Digital Genome Market

10.5 South and Central America: Digital Genome Market

11. Impact of COVID-19 Pandemic on Global Digital Genome Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment of COVID-19 Pandemic

11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Digital Genome Market - Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.4 Inorganic Developments

13. Company Profiles

13.1 Thermo Fisher Scientific Inc.

13.2 F. Hoffmann-La Roche Ltd.

13.3 Illumina, Inc.

13.4 QIAGEN

13.5 GenomeMe

13.6 NanoString Technologies, Inc.

13.7 BD

13.8 bioMerieux SA

13.9 GenMark Diagnostics, Inc.

13.10 Perkin Elmer, Inc.

See the article here:
Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company -...